Nova matches university research with global commercialization opportunities.

The technology transfer agent built on Zima's platform searches every patent and thesis a university holds and returns ranked matches with licensees and investors, in seconds.

Talk to us about Nova

What Nova does

Qualified leads and personalized pitch decks, from one question.

Nova identifies relevant assets, evaluates each for commercialization readiness against the competition, shortlists licensees and investors, and puts together marketing materials tailored to each prospect.

  1. 01Ask

    Ask in plain language, from a field or a single invention.

    Which inventions help CAR-T cells survive longer in patients, and who would license them?

    Invention Immuno-oncology · CAR-T
  2. 02Evaluate

    Licensable or not, on what evidence, against whom.

    Licensing · Evaluate

    Selective expansion switch for engineered immune cells

    Licensee interest 88/100 · High
    Competitive intensity High
    5 franchises4 trials3 public statements
  3. 03Match

    To whom, ranked with reasons, from deals and pipelines on the record.

    Licensing · Lead gen

    Candidate licensees

    StrongComplementary fit3

    1. 1Global pharma, CAR-T franchise91/100 fitOwns two approved CAR-T products. Actively scouting persistence enhancers.
    2. 2Biotech, cell-therapy platform85/100 fitPrioritizing durability for its CAR-T portfolio. Complementary, not competing.
    3. 3Large pharma, next-gen cell therapy72/100 fit
  4. 04Outreach

    An email and a deck, drafted per licensee, ready to send.

    Cover email

    Helping CAR-T cells survive longer in patients

    Proposal deck

    A built-in switch that makes CAR-T cells multiply and persist.

    Draft in Gmail

Built on Zima

Nova is powered by Zima, the company brain above an organization's data.

The same brain that makes a university's research record queryable can make any organization's.

Learn more about Zima